The German drugmaker confirmed acquisition talks, but cautioned a deal may not materialize. Elsewhere, Biohaven got priority review on a key drug and Third Harmonic restructured.

--Traded as low as $85.73; lowest intraday level since Sept. 27, 2022, when it hit $85.67 These undervalued stocks with wide and narrow moats have increased their dividends for 25 consecutive years or ...

Merck Foundation Marks International Day of Girls & Women in Science 2025 by providing Over 1000 Scholarships to Women ...

Merck KGaA, the German healthcare and technology group, said on Monday it is in advanced talks to acquire U.S. cancer and ...

The table below is a review of notable updates that occurred in January 2025 for investigational products in development.

In this piece, we will look at the stocks Jim Cramer recently discussed.

NEW YORK, NY / ACCESS Newswire / February 11, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Merck ...

As SpringWorks Therapeutics nears a key regulatory decision in the U.S., the Connecticut-based cancer and rare disease ...

Germany’s Merck KGaA is in advanced talks for a potential acquisition of SpringWorks Therapeutics, a U.S. biopharmaceutical ...

We recently published a list of 10 Important News Updates Investors Shouldn’t Miss. In this article, we are going to take a ...

Merck KGaA, the German healthcare and technology group, is in advanced talks to acquire U.S. cancer and rare diseases ...

Merck KGaA is in advanced talks to acquire U.S. drugmaker Springworks Therapeutics, potentially impacting the healthcare sector with a sizable move in its cancer treatment pipeline. Springworks' stock ...